PROBABLY NOT. In patients who have hypertension, the timing of administration of antihypertensive medications does not appear to impact cardiovascular outcomes (strength of recommendation: B; contradictory randomized controlled trials).

In addition to 3 vaccines, there's also a new monoclonal antibody for prevention of respiratory syncytial virus. Learn how each can be used in infants and children, adults, and pregnant people.

Given the ubiquity of these plant-based oils, your patients might ask about using them. Here's the evidence on safety and efficacy to guide your response.

► history of Graves disease ► general fatigue, palpitations, and hand tremors.

► myalgias and progressive symmetrical proximal weakness ► history of unilateral renal agenesis, type 2 diabetes, and hyperlipidemia.

Aspirin demonstrated a significantly higher rate of postoperative venous thromboembolic events compared with enoxaparin in this noninferiority study.

Optimizing your care requires that you distinguish between provoked and unprovoked seizures and focus on key elements of the patient's history.

The location of the nodules and the patient's history were important diagnostic clues. The punch biopsy confirmed our suspicions.

A large multicenter trial evaluated effects on pain and function for pediatric patients treated with a soft bandage vs rigid immobilization.

NO. In general, nonoral estrogen use for menopausal symptoms is associated with a lower cardiovascular (CV) risk profile than oral estrogen use (strength of recommendation [SOR], B; meta-analysis of cohort studies). Vaginal estrogen use is associated with lower risk for coronary heart disease (CHD) and similar risk for myocardial infarction (MI), stroke, and deep vein thrombosis/pulmonary embolism (DVT/ PE) compared with nonuse (SOR, B; cohort studies). Vaginal estrogen therapy also is associated with lower CV-related mortality for 3 to 5 years compared withnonuse (SOR, B; cohort study). No high-quality randomized trials address this topic.

A fraction of those eligible for PrEP to prevent HIV infection receive a prescription. Newer drug regimens and updated recommendations can help you reduce that gap.

Nonalcoholic steatohepatitis, or NASH, is the most severe form of nonalcoholic fatty liver disease (NAFLD). If left untreated, NASH can develop into advanced liver disease, such as cirrhosis. Moreover, patients with NASH and cirrhosis are also at increased risk of developing hepatocellular carcinoma. Therefore, early detection and intervention are key components to prevent disease progression, particularly in the primary care setting where many patients with NASH are typically encountered.

Upon completion of this activity, participants will:Have increased knowledge regarding the Mechanistic differences between proton pump inhibitors (PPIs) and potassium-competitive acid blockers (PCABs) Evidence comparing PPIs with PCABs for the treatment of GERD and EE Have greater competence related to Selecting evidence-based treatments for EE.

► intermittent fevers ► recently received second dose of COVID-19 vaccine ► tremors in all 4 extremities.